Samuel D. Waksal

Samuel D. Waksal
Born
Samuel David Waksal

(1947-09-08) September 8, 1947 (age 77)
Paris, France
NationalityAmerican
CitizenshipUnited States
EducationPhD
Alma materOhio State University
Occupation(s)Scientist, biotechnology executive, insider trader
Years active1979–present
Known forFounder of ImClone Systems and Kadmon Pharmaceuticals
Board member ofCadus Corporation, Antigenics Inc., Test University, Rockefeller University
Criminal charge(s)fraud, conspiracy, perjury
Criminal penalty87 months imprisonment
Criminal statusreleased

Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010.[1] At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released.[2]

  1. ^ "Former IMCloe Chief Acquires Drug Company". The New York Times. October 25, 2010. Retrieved September 5, 2016.
  2. ^ "Waksal Gets 7-Plus Years". CNN Money. June 10, 2003. Retrieved September 5, 2016.